- Home
- ALE vs CELC Comparison
ALE vs CELC Comparison
Compare ALE & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALE
- CELC
- Stock Information
- Founded
- ALE 1906
- CELC 2011
- Country
- ALE United States
- CELC United States
- Employees
- ALE N/A
- CELC N/A
- Industry
- ALE Power Generation
- CELC Medical Specialities
- Sector
- ALE Utilities
- CELC Health Care
- Exchange
- ALE Nasdaq
- CELC Nasdaq
- Market Cap
- ALE 3.8B
- CELC 3.1B
- IPO Year
- ALE N/A
- CELC 2017
- Fundamental
- Price
- ALE $67.58
- CELC $100.23
- Analyst Decision
- ALE
- CELC Strong Buy
- Analyst Count
- ALE 0
- CELC 7
- Target Price
- ALE N/A
- CELC $95.29
- AVG Volume (30 Days)
- ALE 614.4K
- CELC 908.4K
- Earning Date
- ALE 10-31-2025
- CELC 11-12-2025
- Dividend Yield
- ALE 4.32%
- CELC N/A
- EPS Growth
- ALE N/A
- CELC N/A
- EPS
- ALE 2.85
- CELC N/A
- Revenue
- ALE $1,500,300,000.00
- CELC N/A
- Revenue This Year
- ALE $2.24
- CELC N/A
- Revenue Next Year
- ALE $5.63
- CELC N/A
- P/E Ratio
- ALE $23.70
- CELC N/A
- Revenue Growth
- ALE N/A
- CELC N/A
- 52 Week Low
- ALE $62.38
- CELC $7.58
- 52 Week High
- ALE $67.60
- CELC $103.06
- Technical
- Relative Strength Index (RSI)
- ALE 64.91
- CELC 78.25
- Support Level
- ALE $67.35
- CELC $92.10
- Resistance Level
- ALE $67.60
- CELC $103.06
- Average True Range (ATR)
- ALE 0.13
- CELC 5.52
- MACD
- ALE -0.04
- CELC 0.74
- Stochastic Oscillator
- ALE 90.57
- CELC 90.84
About ALE Allete Inc.
ALLETE Inc provides competitively-priced energy in America's Upper Midwest region and invests in transmission infrastructure and other energy-centric businesses. The company has two reportable segments. The first segment is Regulated Operations, which includes the company's regulated utilities, Minnesota Power and SWL&P, as well as its investment in ATC. ATC is a regulated utility based in Wisconsin that owns and maintains electric transmission assets in parts of Wisconsin, Michigan, Minnesota, and Illinois. The second segment is ALLETE Clean Energy, which focuses on developing, acquiring, and operating clean and renewable energy projects.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.